Patients with persistent/chronic immune thrombocytopenia (cITP) have low platelet counts, increased risk of bleeding and bruising, and often suffer from reduced health-related quality of life (HRQoL). cITP Improvements from baseline started within 3 months and persisted through 5 years of treatment for FACIT-Fatigue and FACT-Th6 (P <.05 for nearly all time points); through 2.5 years for SF-36v2 PCS and less consistently for the MEI-SF. In conclusion, in addition to eltrombopag increasing platelet counts and reducing bleeding/bruising, it also alleviated fatigue, concerns about bleeding and bruising, and improved physical function in many patients, especially responders.
commonly associated with fatigue and fear of bleeding that can interfere with daily activities. Complications due to bleeding are more common in patients with platelet counts <30 × 10 9 /L, thus, published guidelines recommend ITP treatment initiation in adults when platelet counts fall below 30 × 10 9 /L. [5] [6] [7] Treatment of ITP is intended to increase platelet counts to a hemostatic range to decrease the risk of bleeding; it also seeks to ameliorate the associated reductions in health-related quality of life (HRQoL).
In the past decade, studies have unequivocally demonstrated the substantial impact of cITP on HRQoL. In the first ITP study of HRQoL, scores in adult patients with cITP were not only lower than scores in the general US population, indicating poorer HRQoL, but were also lower than reported HRQoL scores in patients with certain other chronic conditions including hypertension and arthritis. 8 Bleeding episodes and fear of bleeding, unexplained fatigue, nonspecific aches and pains, decreased emotional health, low energy/depression, decreased desire to socialize, and reproductive health issues in men and women including erectile dysfunction and menorrhagia have all been cited as reasons for lower HRQoL scores in patients with cITP. 9, 10 ITP focus groups reported significant impairments in overall HRQoL as described above and reported that reduced HRQoL was due to not only the disease but also side effects associated with its treatment. The most common treatment-related adverse effects were those associated with corticosteroids, the mainstay of ITP therapy, including weight gain, mood swings, anger, and insomnia, and were particularly emphasized as negatively affecting HRQoL. 10 In a survey of over 500 patients with ITP, more than 50% of patients reported feeling "highly bothered" by corticosteroid-induced symptoms. 11 Adverse effects of intravenous immunoglobulin, antiD immunoglobulin, and rituximab therapy have also been reported to have side effects reducing HRQoL. 12 Eltrombopag is an oral thrombopoietin-receptor-agonist approved for the treatment of cITP in adults and children over the age of 1 year who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. [13] [14] [15] [16] Eltrombopag stimulates platelet production by binding to the transmembrane domain of the thrombopoietin receptor and inducing proliferation and differentiation of megakaryocytes. 17, 18 Studies have shown that treatment with eltrombopag often increases platelet counts and is generally well-tolerated by healthy volunteers and patients with cITP, thrombocytopenia caused by hepatitis C-related cirrhosis, and severe aplastic anemia. 13, 14, 19, 20 Increases in platelet counts with long-term treatment with eltrombopag reduce not only the number of bleeding events, but also the need for concomitant and rescue medications. 14 Given the efficacy of eltrombopag in long-term treatment of cITP in EXTEND (Eltrombopag Extended Dosing Study), this analysis explored the effects on HRQoL with continuing eltrombopag treatment.
The specific objectives of this study were to assess: (a) changes from baseline over time in patient-reported HRQoL in all patients and (b) the association between patient-reported HRQoL and platelet response. Platelet counts were assessed weekly during the first 4 weeks, after any dose change, and every 4 weeks throughout the study.
Patients whose platelet counts did not reach the 50 × 10 9 /L threshold were permitted to continue treatment as long as they received benefit and did not experience more than moderate side effects. Willing, responding subjects who did not experience serious side effects and continued to require eltrombopag treatment continued in the study until either eltrombopag became commercially available to them, or a regulatory/reimbursement decision was made (eg, they were switched to commercial eltrombopag or another treatment).
Patient-reported HRQoL was prospectively and longitudinally assessed during long-term eltrombopag treatment in patients with persistent/cITP. Patients were included in the current HRQoL analyses if they had received at least 1 dose of eltrombopag and completed both a baseline assessment of HRQoL and at least one postbaseline assessment in order to assess change in HRQoL.
| Outcomes and covariates
Four HRQoL instruments were used in this study to assess change in HRQoL from baseline as secondary outcomes for EXTEND. 27 The FACT-Th6 was studied for comparative purposes in EXTEND and was not intended for development as a stand-alone instrument. 
| Multivariate analysis
Multivariate analysis of change in HRQoL measures from baseline to 
| RESULTS
The final results of the EXTEND study have been published Table S1 . 30 
| HRQoL at baseline
The number of patients who had a baseline and at least one on- c Generalized estimating equations were used to assess mean best change in HRQoL scores from baseline. The regression models adjusted for demographic and baseline clinical characteristics (BMI [SF-36v2 PCS and domains included in the PCS only] baseline platelet count, baseline use of ITP medication, prior exposure to eltrombopag, prior splenectomy) and indicator of rescue therapy use before best postbaseline score. Patients with missing covariates were excluded from the analyses (17 patients were excluded from the analyses of SF-36v2 PCS and domains included in the PCS due to missing baseline BMI score and 1 additional patient was excluded from all analyses due to another missing covariate). d All P-values < .001. e PCS and MCS scores were normalized so that the 1998 US census general population has a mean of 50 and SD of 10.
| Multivariate analysis of change in HRQoL measures from baseline to different time periods
All HRQoL instruments had positive adjusted mean changes from baseline over time starting at 0-3 months after baseline. Improvements from baseline persisted through 5 years of treatment for FACIT-Fatigue and FACT-Th6 (nearly all P <.05, Table 2 In the present study, baseline HRQoL of patients with persistent/ cITP, as measured by the SF-36v2 instrument, was less than that of the general US population; however, it was similar to scores observed in prior trials of eltrombopag and romiplostim, a peptibody and thrombopoietic agent, and other ITP cohorts. 8, 31, 32 Baseline SF-36v2 and FACIT-Fatigue scores were consistent with shorter-term eltrombopag studies, reflecting impaired HRQoL in cITP patients compared with the general population. 23, 25 Romiplostim has had similar platelet effects in cITP and also demonstrated improvements in HRQoL. 33 Mean baseline scores for each of the instruments in the current study Each of the HRQoL domains and scores used in this study measures some dimension of fatigue, either the symptom itself or its physical and functional impact. As in previous studies of eltrombopag from 6 weeks to 6 months in duration, treatment with eltrombopag was often associated with consistent improvement in HRQoL scores across various domains related to fatigue and physical aspects of HRQoL, suggesting that eltrombopag therapy in patients may be associated with a persisting reduction in fatigue and its impact. 13, 14, 19, 34 While the current study found overall positive mean changes in Table 2 TABLE 3 Adjusted mean HRQoL score changes associated with platelet response in the absence of rescue therapy 
| LIMITATIONS
There are important limitations to this study. The first is the difficulty in identifying which measurements of HRQoL are most important or relevant, either to patients or their clinicians. In this study, however, multiple instruments, based on the suggestions of ITP focus group participants that these questionnaires and items capture unique aspects of ITP and their positive associations with platelet response (using multiple definitions of platelet response), are reassuring in this regard. This study was conducted before development of the BAT and the ITP-PAQ was unavailable for use in this study.
Second, in this long-term study, the number of patients remaining in the trial decreased over time and not all patients completed serial HRQoL assessments. Clear improvements in HRQoL could be seen immediately after baseline, as the sample size was largest at this time.
However, after longer time periods near the end of the study, there
were too few patients with HRQoL assessments to determine an effect. It is very possible that patients who left the trial were doing less well with treatment for one reason or another.
Third, the study population is not directly comparable to the general US population because the clinical trial was multinational and only 26 .8% of patients were from the Americas. Additionally, patients enrolled in a clinical trial may experience different HRQoL than the general population. 
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